Loriot M-A, Beaune P
Inserm UMR-S775, service de toxicologie moléculaire, université René-Descartes, centre universitaire des Saints-Pères, 45, rue des Saints-Pères, 75006 Paris, France.
Rev Med Interne. 2006 Dec;27(12):979-82. doi: 10.1016/j.revmed.2006.09.004. Epub 2006 Oct 11.
Vitamin K epoxide reductase complex subunit I (VKORC1) is a key enzyme in the vitamin K cycle, cofactor required for the activation of vitamin K-dependent clotting factors.
VKORC1 recycles vitamin K 2,3 epoxide back to active vitamin K hydroquinone, an important factor for the carboxylation step of clotting factors. VKORC1 is the target enzyme of inhibition by oral anticoagulants or anti-vitamin K (warfarin, acenocoumarol).
We show here the clinical consequences of genetic variations of VKORC1 during VKA therapy.
维生素K环氧化物还原酶复合体亚基I（VKORC1）是维生素K循环中的关键酶，是维生素K依赖性凝血因子激活所需的辅因子。
VKORC1将维生素K 2,3环氧化物循环回活性维生素K氢醌，这是凝血因子羧化步骤的重要因素。VKORC1是口服抗凝剂或抗维生素K（华法林、醋硝香豆素）抑制的靶酶。
我们在此展示了VKA治疗期间VKORC1基因变异的临床后果。
